Stem cells in the treatment of diabetes mellitus — Focus on mesenchymal stem cells
Diabetes mellitus type 1 and type 2 have become a global epidemic with dramatically increasing incidences. Poorly controlled diabetes is associated with severe life-threatening complications. Beside traditional treatment with insulin and oral anti-diabetic drugs, clinicians try to improve patient's care by cell therapies using embryonic stem cells (ESC), induced pluripotent stem cells (iPSC) and adult mesenchymal stem cells (MSC). ESC display a virtually unlimited plasticity, including the differentiation into insulin producing β-cells, but they raise ethical concerns and bear, like iPSC, the risk of tumours.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: G ünter Päth, Nikolaos Perakakis, Christos S. Mantzoros, Jochen Seufert Tags: Review Source Type: research
More News: Biomedical Science | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Epidemics | Epidemiology | Insulin | Medical Ethics | Stem Cell Therapy | Stem Cells